CareMax Valuation

Is CMAX.Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CMAX.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CMAX.Q's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CMAX.Q's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CMAX.Q?

Key metric: As CMAX.Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CMAX.Q. This is calculated by dividing CMAX.Q's market cap by their current revenue.
What is CMAX.Q's PS Ratio?
PS Ratio	0.002x
Sales	US$784.55m
Market Cap	US$1.61m

CMAX.Q key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	-4.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CMAX.Q's PS Ratio compare to its peers?

The above table shows the PS ratio for CMAX.Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
GBNH.F Greenbrook TMS	0.02x	n/a	US$1.9m
OHCS Optimus Healthcare Services	2.3x	n/a	US$3.3m
NVOS Novo Integrated Sciences	0.06x	n/a	US$838.4k
SYRA Syra Health	1x	n/a	US$7.6m
CMAX.Q CareMax	0.002x	26.0%	US$1.6m

Price-To-Sales vs Peers: CMAX.Q is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does CMAX.Q's PS Ratio compare vs other companies in the US Healthcare Industry?

30 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.1x	6.6%
CMAX.Q CareMax	0.002x	26.0%	US$1.61m
MCK McKesson	0.2x	8.1%	US$79.78b
CVS CVS Health	0.2x	4.5%	US$75.32b

30 Companies		Estimated Growth	Market Cap
Industry Avg.	1.1x	20.9%
CMAX.Q CareMax	0.002x	77.2%	US$1.61m

No more companies

Price-To-Sales vs Industry: CMAX.Q is good value based on its Price-To-Sales Ratio (0x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is CMAX.Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CMAX.Q PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.002x
Fair PS Ratio	0.1x

Price-To-Sales vs Fair Ratio: CMAX.Q is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.49

5.0%

-19.4%

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

-0.6%

-19.9%

Progyny

US$1.3b

A benefits management company, specializes in fertility and family building benefits solutions in the United States.

PGNY

US$15.57

0.8%

-55.0%